Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer

NCT00569335 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal, Cancer

Interventions

DRUG: S-1, Irinotecan, Bevacizumab

Sponsor

Taiho Pharmaceutical Co., Ltd.